News | Left Atrial Appendage (LAA) Occluders | March 16, 2016

Valley Hospital Begins Enrollment for aMAZE Trial

New Jersey hospital one of 15 U.S. sites for trial evaluating Lariat suture delivery device for treatment of atrial fibrillation

aMAZE Trial enrollment, The Valley Hospital NJ, atrial fibrillation

March 16, 2016 — The Valley Hospital in Ridgewood, N.J., is one of 15 U.S. sites currently enrolling patients in a research study evaluating a potential new treatment for patients with symptomatic persistent and long standing persistent atrial fibrillation (AFib).

The aMAZE Trial is evaluating an innovative treatment approach that combines catheter ablation with the use of a device called the Lariat to close off the heart’s left atrial appendage (LAA). Just as the name implies, the Lariat uses a lasso-like stitch to tie off the LAA — a muscular pouch connected to the left atrium of the heart that is the major source of blood clots in patients with atrial fibrillation that can lead to a stroke. The LAA may also be a source of abnormal electrical activity that triggers AFib. The trial will evaluate whether the combination of the two treatment approaches may treat persistent AFib more effectively than catheter abolition alone.

“We are pleased to be one of the first sites in the U.S. to enroll patients in the aMAZE Trial,” said Dan Musat, M.D., principal investigator for the aMAZE Trial at Valley. “We are optimistic that we will be able to show that combining the two approaches is an effective option for patients with persistent AFib.”

AFib is an irregular heartbeat, a rapid heartbeat or a quivering of the upper chambers of the heart, called the atria, due to a malfunction in the heart's electrical system. It is the most common heart rhythm disorder in the United States, affecting more than 5 million people. Because the heart is not beating effectively, blood can pool in the upper chambers of the heart and form a clot, typically in the left atrial appendage. If the clot then travels from the heart to the brain, it can cause a stroke.

“This is a potential milestone in the treatment of atrial fibrillation” said Suneet Mittal, M.D., director of electrophysiology at Valley. “AFib is a life-changing disorder that causes devastating consequences, including stroke and congestive heart failure. Using the Lariat device as an adjunct to conventional ablation could become the standard of care for patients with persistent and/or long-standing persistent AFib.”

In a recently published study, the Lariat used as an adjunct to ablation in patients with persistent or long-standing persistent AFib showed a 65 percent freedom from AFib at one year compared with 39 percent in patients with ablation alone. Other studies have demonstrated that the device not only closes the LAA mechanically, but can also isolate electrical activity within the LAA — a known trigger for AFib, shown to contribute abnormal electrical activity in a significant percentage of patients.

The objective of the aMAZE trial is to demonstrate that the Lariat will reduce or eliminate these LAA triggers and, when combined with ablation, will lead to a reduced incidence of recurrent AFib compared to ablation alone, with a high safety profile.

The Lariat is a permanent, non-implant solution to LAA closure that is being studied for its capabilities to both mechanically and electrically isolate the LAA in patients with AFib. The device utilizes remote suture delivery to close the LAA from the outside of the heart in a precise and controlled manner.

The aMAZE trial is comprised of two stages. The overall study plan is to enroll a maximum of 600 persistent or longstanding persistent AFib patients who are candidates for catheter ablation at up to 50 centers. The first stage of the trial, underway now, will enroll up to 175 patients at 15 centers.

For more information: www.sentreheart.com

Related Content

The TactiFlex PAF investigational device exemption (IDE) study will evaluate he investigational TactiFlex Ablation Catheter, Sensor Enabled (SE) to treat people suffering from paroxysmal atrial fibrillation (PAF). 

The TactiFlex PAF investigational device exemption (IDE) study will evaluate he investigational TactiFlex Ablation Catheter, Sensor Enabled (SE) to treat people suffering from paroxysmal atrial fibrillation (PAF). 

News | Atrial Fibrillation | August 04, 2020
August 4, 2020 — Abbott announced the first enrollments in the TactiFlex PAF  investigational device exemption (IDE)
PREDICT-AF trial showed first time there is extensive extracellular matrix remodeling. #HRS2020 #Heartrhythm2020. Marilyn Fornell
News | Atrial Fibrillation | May 19, 2020
May 19, 2020 — Structural changes of the atrium may occur long before the onset of atrial fibrillation (AF), and the
Results of the Atrial Fibrosis Predicts Recurrent Stroke Or New Atrial Fibrillation In Patients With Embolic Stroke Of Undetermined Source - A Multi-Center Study at HRS 2020. #HRS2020 #Heartrhythm2020,
News | Atrial Fibrillation | May 19, 2020
May 19, 2020 — Atrial disease has been implicated in embolic stroke of undetermined source (ESUS) and a late-breaking
Contact Force Sensing Catheter Improved Outcomes in Persistent Atrial Fibrillation Ablation. #HRS2020 #heartrhythm2020
News | Atrial Fibrillation | May 13, 2020
May 13, 2020 — The PRECEPT study testing the use of the Biosense Webster Thermocool Smarttouch SF Catheter for the tr
The Swiss-AF study shows High Incidence Of Silent Brain Infarcts Found in Anticoagulated Atrial Fibrillation Patients. #Heartrhythm2020 #HRS20 #HRS2020
News | Atrial Fibrillation | May 08, 2020
May 8, 2020 – A new clinical study found that patients with...
PINNACLE FLX Study of New Watchman FLX LAA Occluder Meets Safety and Efficacy Endpoints. #Heartrhythm2020 #HRS20 #HRS2020
News | Atrial Fibrillation | May 08, 2020
May 8, 2020 — Positive 12-month results were announced today from the...
The first-in-human results show positive results for Medtronic's pulsed field ablation in safety and efficiency. #Heartrhythm2020 #HRS2020 #HRS20
News | Atrial Fibrillation | May 08, 2020
May 8, 2020 — New clinical trial reveals the first-in-human results for paroxysmal or persistent atrial fibrillation
POPULAR TAVR trial Shows Oral Anticoagulants Alone in atrial fibrillation  (AF) Patients Reduces Bleeding Post TAVR, transcatheter aortic valve replacement. #ACC20 #ACC2020
News | Atrial Fibrillation | March 29, 2020
March 29, 2020 — Patients with atrial fibrillation (AF) who took oral anticoagulants alone after undergoing transcath
Medtronic's PulseSelect Pulsed Field Ablation (PFA) System

Medtronic's PulseSelect Pulsed Field Ablation (PFA) System.

News | Atrial Fibrillation | January 31, 2020
January 31, 2020 – The U.S.
Frequent Drinking Greater Risk Factor for Heart Rhythm Disorder Than Binge Drinking

Image courtesy of the American Heart Association.

News | Atrial Fibrillation | October 22, 2019
October 22, 2019 —  Drinking small amounts of alcohol frequently is linked with a higher likelihood of...